RM

Rafeeq Mothirapeedika Abhoobaker Mohamed

Active Director Director DIN 11407865
DIN 11407865 First appointment Dec 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Rafeeq Mothirapeedika Abhoobaker Mohamed

Data last updated:

Rafeeq Mothirapeedika Abhoobaker Mohamed is a Director at Curay Pharma Private Limited (since 2025).

DIN 11407865
Primary Designation Director
First Appointment 03 Dec 2025

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Curay Pharma Private Limited U46497KL2025PTC098851
Director03 Dec 20252025Active

Board colleagues of Rafeeq Mothirapeedika Abhoobaker Mohamed

Directorship timeline

Open interactive timeline →
Curay Pharma Private Limited
Premium access

Shareholding and investment profile for Rafeeq Mothirapeedika Abhoobaker Mohamed

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rafeeq Mothirapeedika Abhoobaker Mohamed

Rafeeq Mothirapeedika Abhoobaker Mohamed currently holds 1 directorship: Curay Pharma Private Limited (Director, since 03 Dec 2025).

Rafeeq Mothirapeedika Abhoobaker Mohamed was first appointed on 03 Dec 2025 as Director at Curay Pharma Private Limited.

The current boards of Rafeeq Mothirapeedika Abhoobaker Mohamed's companies include Abdul Nasar Kolambil (Curay Pharma Private Limited), Mohammed Kabeer Poola Kuzhiyil (Curay Pharma Private Limited), Seelath Ramees Jawhar (Curay Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available